Submissions from 2024
Management of Factor Xa Inhibitor-Related Traumatic Non-Intracranial Bleeding Events with Andexanet Alfa or Four-Factor Prothrombin Complex Concentrate in a US Multicenter Observational Study, Paul P. Dobesh, Craig I. Coleman, Mark Danese, Eva Lesén, Raymond C. Chang, Onivefu Odelade, and Gregory J. Fermann
Andexanet Alfa Versus PCC Products for Factor Xa Inhibitor Bleeding: A Systematic Review with Meta-Analysis, C. Michael White, Kimberly Snow Caroti, Youssef Bessada, Adrian V. Hernandez, William L. Baker, Paul P. Dobesh, Heleen van Haalen, Kirsty Rhodes, and Craig I. Coleman
Submissions from 2023
Lower Mortality with Andexanet Alfa vs 4-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-Related Major Bleeding in a U.S. Hospital-Based Observational Study, Paul P. Dobesh, Gregory J. Fermann, Mary J. Christoph, Bruce Koch, Eva Lesén, Hungta Chen, Belinda Lovelace, Theresa Dettling, Mark Danese, Julie Ulloa, Sherry Danese, and Craig I. Coleman
Submissions from 2016
Treatment of a chemoresistant neuroblastoma cell line with the antimalarial ozonide OZ513., Don W. Coulter, Timothy R. McGuire, J. Graham Sharp, Erin M. McIntyre, Yuxiang Dong, Xiaofang Wang, Shawn Gray, Gracey R. Alexander, Nagendra K. Chatuverdi, Shantaram Joshi, Xiaoyu Chen, and Jonathan L. Vennerstrom
Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism., Maureen A. Smythe, Jennifer Priziola, Paul P. Dobesh, Diane Wirth, Adam Cuker, and Ann K. Wittkowsky
Submissions from 2015
Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities., Paul P. Dobesh and John Fanikos
Impact of a high-fat meal on assessment of clopidogrel-induced platelet inhibition in healthy subjects., Paul P. Dobesh, Jamela F. Urban, Scott W. Shurmur, and Julie H. Oestreich
Submissions from 2014
New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities., Paul P. Dobesh and John Fanikos
Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety., Paul P. Dobesh and Julie H. Oestreich
Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications., Toby Trujillo and Paul P. Dobesh